Cargando…

In Silico Vaccine Design and Expression of the Multi-Component Protein Candidate against the Toxoplasma gondii Parasite from MIC13, GRA1, and SAG1 Antigens

BACKGROUND: We aimed to design a B and T cell recombinant protein vaccine of Toxoplasma gondii with in silico approach. MIC13 plays an important role in spreading the parasite in the host body. GRA1 causes the persistence of the parasite in the parasitophorous vacuole. SAG1 plays a role in host-cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosseininejad, Zahra, Daryani, Ahmad, Fasihi-Ramandi, Mahdi, Asgarian-Omran, Hossein, Valadan, Reza, Nayeri, Tooran, Dodangeh, Samira, Sarvi, Shahabeddin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597883/
https://www.ncbi.nlm.nih.gov/pubmed/37886246
http://dx.doi.org/10.18502/ijpa.v18i3.13753
_version_ 1785125442820243456
author Hosseininejad, Zahra
Daryani, Ahmad
Fasihi-Ramandi, Mahdi
Asgarian-Omran, Hossein
Valadan, Reza
Nayeri, Tooran
Dodangeh, Samira
Sarvi, Shahabeddin
author_facet Hosseininejad, Zahra
Daryani, Ahmad
Fasihi-Ramandi, Mahdi
Asgarian-Omran, Hossein
Valadan, Reza
Nayeri, Tooran
Dodangeh, Samira
Sarvi, Shahabeddin
author_sort Hosseininejad, Zahra
collection PubMed
description BACKGROUND: We aimed to design a B and T cell recombinant protein vaccine of Toxoplasma gondii with in silico approach. MIC13 plays an important role in spreading the parasite in the host body. GRA1 causes the persistence of the parasite in the parasitophorous vacuole. SAG1 plays a role in host-cell adhesion and cell invasion. METHODS: Amino acid positions 73–272 from MIC13, 71–190 from GRA1, and 101–300 from SAG1 were selected and joined with linker A(EAAAK)A. The structures, antigenicity, allergenicity, physicochemical properties, as well as codon optimization and mRNA structure of this recombinant protein called MGS1, were predicted using bioinformatics servers. The designed structure was synthesized and then cloned in pET28a (+) plasmid and transformed into Escherichia coli BL21. RESULTS: The number of amino acids in this antigen was 555, and its antigenicity was estimated to be 0.6340. SDS-PAGE and Western blotting confirmed gene expression and successful production of the protein with a molecular weight of 59.56kDa. This protein will be used in our future studies as an anti-Toxoplasma vaccine candidate in animal models CONCLUSION: In silico methods are efficient for understanding information about proteins, selecting immunogenic epitopes, and finally producing recombinant proteins, as well as reducing the time and cost of vaccine design.
format Online
Article
Text
id pubmed-10597883
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Tehran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-105978832023-10-26 In Silico Vaccine Design and Expression of the Multi-Component Protein Candidate against the Toxoplasma gondii Parasite from MIC13, GRA1, and SAG1 Antigens Hosseininejad, Zahra Daryani, Ahmad Fasihi-Ramandi, Mahdi Asgarian-Omran, Hossein Valadan, Reza Nayeri, Tooran Dodangeh, Samira Sarvi, Shahabeddin Iran J Parasitol Original Article BACKGROUND: We aimed to design a B and T cell recombinant protein vaccine of Toxoplasma gondii with in silico approach. MIC13 plays an important role in spreading the parasite in the host body. GRA1 causes the persistence of the parasite in the parasitophorous vacuole. SAG1 plays a role in host-cell adhesion and cell invasion. METHODS: Amino acid positions 73–272 from MIC13, 71–190 from GRA1, and 101–300 from SAG1 were selected and joined with linker A(EAAAK)A. The structures, antigenicity, allergenicity, physicochemical properties, as well as codon optimization and mRNA structure of this recombinant protein called MGS1, were predicted using bioinformatics servers. The designed structure was synthesized and then cloned in pET28a (+) plasmid and transformed into Escherichia coli BL21. RESULTS: The number of amino acids in this antigen was 555, and its antigenicity was estimated to be 0.6340. SDS-PAGE and Western blotting confirmed gene expression and successful production of the protein with a molecular weight of 59.56kDa. This protein will be used in our future studies as an anti-Toxoplasma vaccine candidate in animal models CONCLUSION: In silico methods are efficient for understanding information about proteins, selecting immunogenic epitopes, and finally producing recombinant proteins, as well as reducing the time and cost of vaccine design. Tehran University of Medical Sciences 2023 /pmc/articles/PMC10597883/ /pubmed/37886246 http://dx.doi.org/10.18502/ijpa.v18i3.13753 Text en © 2023 Hosseininejad et al. Published by Tehran University of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
spellingShingle Original Article
Hosseininejad, Zahra
Daryani, Ahmad
Fasihi-Ramandi, Mahdi
Asgarian-Omran, Hossein
Valadan, Reza
Nayeri, Tooran
Dodangeh, Samira
Sarvi, Shahabeddin
In Silico Vaccine Design and Expression of the Multi-Component Protein Candidate against the Toxoplasma gondii Parasite from MIC13, GRA1, and SAG1 Antigens
title In Silico Vaccine Design and Expression of the Multi-Component Protein Candidate against the Toxoplasma gondii Parasite from MIC13, GRA1, and SAG1 Antigens
title_full In Silico Vaccine Design and Expression of the Multi-Component Protein Candidate against the Toxoplasma gondii Parasite from MIC13, GRA1, and SAG1 Antigens
title_fullStr In Silico Vaccine Design and Expression of the Multi-Component Protein Candidate against the Toxoplasma gondii Parasite from MIC13, GRA1, and SAG1 Antigens
title_full_unstemmed In Silico Vaccine Design and Expression of the Multi-Component Protein Candidate against the Toxoplasma gondii Parasite from MIC13, GRA1, and SAG1 Antigens
title_short In Silico Vaccine Design and Expression of the Multi-Component Protein Candidate against the Toxoplasma gondii Parasite from MIC13, GRA1, and SAG1 Antigens
title_sort in silico vaccine design and expression of the multi-component protein candidate against the toxoplasma gondii parasite from mic13, gra1, and sag1 antigens
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597883/
https://www.ncbi.nlm.nih.gov/pubmed/37886246
http://dx.doi.org/10.18502/ijpa.v18i3.13753
work_keys_str_mv AT hosseininejadzahra insilicovaccinedesignandexpressionofthemulticomponentproteincandidateagainstthetoxoplasmagondiiparasitefrommic13gra1andsag1antigens
AT daryaniahmad insilicovaccinedesignandexpressionofthemulticomponentproteincandidateagainstthetoxoplasmagondiiparasitefrommic13gra1andsag1antigens
AT fasihiramandimahdi insilicovaccinedesignandexpressionofthemulticomponentproteincandidateagainstthetoxoplasmagondiiparasitefrommic13gra1andsag1antigens
AT asgarianomranhossein insilicovaccinedesignandexpressionofthemulticomponentproteincandidateagainstthetoxoplasmagondiiparasitefrommic13gra1andsag1antigens
AT valadanreza insilicovaccinedesignandexpressionofthemulticomponentproteincandidateagainstthetoxoplasmagondiiparasitefrommic13gra1andsag1antigens
AT nayeritooran insilicovaccinedesignandexpressionofthemulticomponentproteincandidateagainstthetoxoplasmagondiiparasitefrommic13gra1andsag1antigens
AT dodangehsamira insilicovaccinedesignandexpressionofthemulticomponentproteincandidateagainstthetoxoplasmagondiiparasitefrommic13gra1andsag1antigens
AT sarvishahabeddin insilicovaccinedesignandexpressionofthemulticomponentproteincandidateagainstthetoxoplasmagondiiparasitefrommic13gra1andsag1antigens